Eviplera/Complera (rilpivirine, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, both products contain emtricitabine and tenofovir-DF and must not be administered with other products containing emtricitabine and tenofovir-DF.
Eviplera should not be administered concomitantly with other medicinal products containing emtricitabine or tenofovir disoproxil.
Eviplera Summary of Product Information, Gilead Sciences Ltd, August 2021.
Because Complera is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.
Complera US Prescribing Information, Gilead Sciences Inc, November 2019.
Emtricitabine/tenofovir-DF should not be administered concomitantly with other medicinal products containing emtricitabine or tenofovir disoproxil.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking